Skip to main
AVTX
AVTX logo

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics has recently demonstrated a notable increase in stock value, rising approximately 22% in pre-market trading, reflecting growing investor confidence in AVTX-009's potential as the company approaches the LOTUS data readout. The market for inflammatory disease treatments, particularly in hidradenitis suppurativa (HS), is anticipated to experience substantial growth due to increasing access to more effective therapies, such as AVTX-009. Additionally, the positive expectation for the performance of AVTX-009 within this expanding market underscores a favorable outlook for Avalo's financial trajectory.

Bears say

Avalo Therapeutics Inc. faces significant challenges, highlighted by reported cases of neutropenia, including one incident of Grade 3 neutrophil count decrease, which could raise safety concerns among potential stakeholders. The competitive landscape is further complicated by the presence of other therapies like lutikizumab, which may possess limitations in efficacy due to target distraction, adversely affecting Avalo’s prospects. Additionally, the overall low rate of diagnosis and treatment for immune dysregulation conditions suggests a constrained market opportunity, diminishing the potential for Avalo's pipeline assets to achieve commercial success.

Avalo Therapeutics (AVTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Avalo Therapeutics (AVTX) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.